Eqis Capital Management Inc. reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.1% during the second quarter, Holdings Channel reports. The institutional investor owned 6,737 shares of the medical equipment provider’s stock after selling 517 shares during the period. Eqis Capital Management Inc.’s holdings in Hologic were worth $306,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp increased its position in Hologic by 1.5% in the first quarter. State Street Corp now owns 12,710,718 shares of the medical equipment provider’s stock valued at $540,846,000 after buying an additional 189,572 shares in the last quarter. Victory Capital Management Inc. increased its position in Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock valued at $172,363,000 after buying an additional 3,269,503 shares in the last quarter. Bank of Montreal Can increased its position in Hologic by 6.6% in the second quarter. Bank of Montreal Can now owns 3,418,319 shares of the medical equipment provider’s stock valued at $155,123,000 after buying an additional 211,550 shares in the last quarter. American Century Companies Inc. increased its position in Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock valued at $134,668,000 after buying an additional 2,204,085 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Hologic by 6.4% in the first quarter. Geode Capital Management LLC now owns 3,116,366 shares of the medical equipment provider’s stock valued at $132,440,000 after buying an additional 186,854 shares in the last quarter. 94.09% of the stock is owned by institutional investors.
Shares of Hologic, Inc. (NASDAQ HOLX) opened at 45.14 on Thursday. The stock has a market cap of $12.64 billion, a PE ratio of 16.19 and a beta of 0.91. Hologic, Inc. has a 1-year low of $35.15 and a 1-year high of $46.80. The company’s 50-day moving average price is $45.13 and its 200 day moving average price is $42.85.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.04. Hologic had a return on equity of 25.26% and a net margin of 27.31%. The firm had revenue of $715.40 million during the quarter, compared to analyst estimates of $685.24 million. During the same quarter last year, the firm earned $0.47 EPS. Hologic’s quarterly revenue was up 3.2% on a year-over-year basis. Equities analysts forecast that Hologic, Inc. will post $2.01 EPS for the current fiscal year.
WARNING: This piece of content was reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/eqis-capital-management-inc-decreases-position-in-hologic-inc-holx/1290937.html.
HOLX has been the subject of several research reports. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Stifel Nicolaus lifted their price objective on Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, May 11th. Leerink Swann reiterated an “outperform” rating and issued a $52.00 price objective on shares of Hologic in a research note on Thursday, March 30th. Piper Jaffray Companies reiterated a “buy” rating and issued a $51.00 price objective on shares of Hologic in a research note on Friday, July 14th. Finally, BidaskClub cut Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company’s stock. Hologic currently has a consensus rating of “Buy” and an average price target of $47.79.
In other Hologic news, Director Lawrence M. Levy sold 2,960 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $44.54, for a total transaction of $131,838.40. Following the completion of the sale, the director now owns 45,634 shares in the company, valued at approximately $2,032,538.36. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Karleen Marie Oberton sold 4,704 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 73,765 shares of company stock valued at $3,261,148. 0.79% of the stock is owned by insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with our FREE daily email newsletter.